查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573230

化療引起的周邊神經病變治療市場：依治療類型、治療階段、患者特徵、治療環境、治療持續時間、藥物作用機制 - 2025-2030 年全球預測

Chemotherapy Induced Peripheral Neuropathy Treatment Market by Treatment Types, Stages Of Treatment, Patient Demographics, Treatment Settings, Duration Of Treatment, Drug Mechanism Of Action - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

化療引起的周邊神經神經病變治療市場2023年估值為9.0535億美元，預計2024年將達到9.7424億美元，複合年成長率為7.91%，到2030年將達15%，預計將達到4328兆美元。

化療引起的周邊神經病變（CIPN）是癌症治療的常見副作用，其特徵是化療藥物引起周邊神經損傷。對有效 CIPN 治療的需求源於改善患者生活品質和提高正在進行的癌症治療的耐受性的需要。應用範圍包括神經保護劑和鎮痛藥等藥物干預、物理治療等非藥物治療以及基因治療和醫療設備等實驗方法。最終用戶主要是醫院、腫瘤中心和研究機構。

主要市場統計
基準年[2023] 90535萬美元
預測年份 [2024] 97424萬美元
預測年份 [2030] 15.4328億美元
複合年成長率（%） 7.91%

市場成長要素包括癌症發生率上升、全球化療使用增加以及患者對治療副作用的認知不斷提高，這些都推動了 CIPN 治療的需求。技術的進步和正在進行的研究正在創造利潤豐厚的機會，提供開發新藥和針對基因譜量身定做的個人化醫療等可能性。為了利用這些優勢，相關人員應該投資於研發，促進生技公司之間的合作，並加強對 CIPN 治療的市場宣導活動。

CIPN 病理學的複雜性使得開拓治療方法變得困難，而高昂的研發成本和監管障礙又減緩了產品的推出。此外，患者對治療反應的可變性使有效治療方法的標準化變得複雜。應對這些挑戰需要增加基礎研究資金、簡化監管途徑並增加國際臨床試驗以統一護理標準。

創新領域在於開發副作用最小的標靶治療、利用即時資料分析進行病患監測以及探索具有治療潛力的天然化合物。未滿足需求的規模凸顯了市場競爭，正在促使大型製藥公司和學術機構之間進行合作，以加速治療進展。專注於以患者為中心的方法，將人工智慧融入臨床研究以進行預測分析，以及開拓的多功能治療平台將顯著推動市場成長，並確保 CIPN 治療領域的業務持續擴張。

市場動態：快速發展的化療引起的周邊神經病變治療市場的關鍵市場洞察

化療引起的周邊神經神經病變治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 擴大發展中地區的醫療基礎設施和服務範圍
    • 製藥公司與研究機構之間的新療法合作
    • 支持癌症治療和神經病變管理的政府措施和資金
    • 將遠端醫療和數位健康解決方案整合到神經病變治療通訊協定中
  • 市場限制因素
    • 化療周邊神經病變的臨床試驗設計所面臨的挑戰
    • 化療引起的周邊神經病變新治療方法獲得核准的監管障礙
  • 市場機會
    • 與製藥公司合作開發針對化療引起的周邊神經病變的創新藥物配方
    • 利用人工智慧和機器學習為化療引起的周邊神經神經病變制定個人化治療計劃
    • 探索飲食和生活方式干涉措施以補充傳統化療引起的周邊神經病變治療
  • 市場挑戰
    • 解決化療引起的周邊神經病變合併治療的複雜性
    • 神經病變治療市場的臨床試驗設計與病患招募挑戰

波特的五力：導航化療引起的周邊神經病變治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解化療引起的周邊神經病變治療市場的外部影響

外部宏觀環境因素在塑造化療引起的周邊神經神經病變治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解化療引起的周邊神經病變治療市場的競爭格局

對化療引起的周邊神經神經病變治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位基質化療誘發周邊神經神經病變治療市場供應商的表現評估

FPNV 定位矩陣是評估化療引起的周邊神經病變治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了化療引起的周邊神經病變治療市場的成功之路

對化療引起的周邊神經神經病變治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 擴大發展中地區的醫療基礎設施和服務範圍
      • 製藥公司與研究機構聯合研究新治療方法
      • 支持癌症治療和神經病變管理的政府措施和資金
      • 將遠端醫療和數位健康解決方案整合到神經病變治療通訊協定中
    • 抑制因素
      • 治療化療引起的周邊神經病變的臨床試驗設計面臨的挑戰
      • 核准化療引起的周邊神經病變新治療方法的監管障礙
    • 機會
      • 與製藥公司合作開發針對化療引起的周邊神經病變的創新藥物配方
      • 利用人工智慧和機器學習為化療引起的周邊神經神經病變制定個人化治療計劃
      • 檢查飲食和生活方式干涉措施以補充傳統化療引起的周邊神經病變治療
    • 任務
      • 化療引起的周邊神經病變合併治療的複雜性
      • 神經病變治療市場中臨床試驗設計與病患招募的挑戰
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章化療引起的周邊神經病變治療市場（依治療類型）

  • 非藥物治療
    • 針刺
    • 認知行為療法
    • 職能治療
    • 物理治療
    • 經皮神經電刺激 (TENS)
  • 藥物治療
    • 抗驚厥藥
    • 抗憂鬱症
    • 食品補充品
    • 鴉片類止痛藥
    • 外用製劑

第7章化療引起的周邊神經病變治療市場（依治療階段）

  • 高級階段
  • 最初的
  • 中場

第8章化療引起的周邊神經神經病變治療市場病人細分

  • 年齡層
    • 成人用
    • 老年病
    • 小兒科
  • 性別
    • 女士
    • 男人
  • 患者病歷
    • 遺傳因素
    • 既往病史
    • 既往化療

第9章化療引起的周邊神經病變治療市場（依治療環境）

  • 居家護理
  • 醫院
  • 專科診所

第10章化療引起的周邊神經神經病變治療市場（依治療持續時間分類）

  • 長期
  • 短期

第11章化療引起的周邊神經神經病變治療市場藥物按作用機制

  • 鈣離子通道調節劑
  • γ-胺基丁酸 (GABA) 類似物
  • 鴉片類藥物
  • 正腎上腺素再回收抑制劑(SNRI)

第12章美洲化療引起的周邊神經神經病變治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太地區化療引起的周邊神經神經病變治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲化療引起的周邊神經神經病變治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C04DA

The Chemotherapy Induced Peripheral Neuropathy Treatment Market was valued at USD 905.35 million in 2023, expected to reach USD 974.24 million in 2024, and is projected to grow at a CAGR of 7.91%, to USD 1,543.28 million by 2030.

Chemotherapy Induced Peripheral Neuropathy (CIPN) is a prevalent adverse effect of cancer treatment, characterized by damage to the peripheral nerves due to chemotherapy drugs. The necessity for effective CIPN treatment stems from the need to improve patients' quality of life and enhance the tolerability of ongoing cancer therapies. The application scope encompasses pharmaceutical interventions like neuroprotective agents and analgesics, non-pharmacological therapies such as physical therapy, and experimental approaches including gene therapy and medical devices. End-users primarily include hospitals, oncology centers, and research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 905.35 million
Estimated Year [2024] USD 974.24 million
Forecast Year [2030] USD 1,543.28 million
CAGR (%) 7.91%

Market growth factors include the rising incidence of cancer, increasing chemotherapy usage globally, and growing patient awareness about treatment side effects, driving demand for CIPN therapies. Technological advancements and ongoing research offer potentials like novel drug development and personalized medicine tailored to genetic profiles, presenting lucrative opportunities. To capitalize on these, stakeholders should invest in R&D, foster collaborations among biotech firms, and enhance market education initiatives about CIPN treatments.

However, several limitations challenge market expansion: the complexity of CIPN pathology makes treatment development difficult, alongside high R&D costs and regulatory hurdles delaying product launches. Additionally, variability in patient responses to treatments complicates the standardization of effective therapies. Addressing these challenges requires increased funding for basic research, streamlined regulatory pathways, and more international clinical trials to unify treatment standards.

Innovation areas lie in developing targeted therapies with minimal side effects, employing real-time data analytics for patient monitoring, and exploring natural compounds with therapeutic potential. The market's competitive nature is underscored by substantial unmet needs, prompting alliances among pharmaceutical giants and academic institutions to expedite therapy advancements. Emphasizing patient-centric approaches, integrating AI in clinical studies for predictive analyses, and developing multifunctional treatment platforms could significantly propel market growth, ensuring sustainable business expansion in the CIPN treatment landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chemotherapy Induced Peripheral Neuropathy Treatment Market

The Chemotherapy Induced Peripheral Neuropathy Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of healthcare infrastructure and access in developing regions
    • Collaborations between pharmaceutical companies and research institutions for novel therapies
    • Government initiatives and funding to support cancer treatment and neuropathy management
    • Integration of telemedicine and digital health solutions in neuropathy treatment protocols
  • Market Restraints
    • Challenges in clinical trial design for chemotherapy induced peripheral neuropathy treatments
    • Regulatory hurdles in gaining approval for new chemotherapy induced peripheral neuropathy therapies
  • Market Opportunities
    • Collaborating with pharmaceutical companies for breakthrough drug formulations targeting chemotherapy induced peripheral neuropathy
    • Utilizing artificial intelligence and machine learning for personalized treatment plans in chemotherapy induced peripheral neuropathy
    • Exploring dietary and lifestyle interventions to complement traditional chemotherapy induced peripheral neuropathy treatments
  • Market Challenges
    • Navigating the complexities of combination treatments for chemotherapy-induced peripheral neuropathy
    • Challenges in clinical trial design and patient recruitment in neuropathy treatment market

Porter's Five Forces: A Strategic Tool for Navigating the Chemotherapy Induced Peripheral Neuropathy Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chemotherapy Induced Peripheral Neuropathy Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chemotherapy Induced Peripheral Neuropathy Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

A detailed market share analysis in the Chemotherapy Induced Peripheral Neuropathy Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chemotherapy Induced Peripheral Neuropathy Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

A strategic analysis of the Chemotherapy Induced Peripheral Neuropathy Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Induced Peripheral Neuropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Asahi Kasei Corporation, Astellas Pharma Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Ipsen Pharma, Johnson & Johnson, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Purdue Pharma L.P., Regenacy Pharmaceuticals LLC, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Induced Peripheral Neuropathy Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Types, market is studied across Non-Pharmacological Treatments and Pharmacological Treatments. The Non-Pharmacological Treatments is further studied across Acupuncture, Cognitive Behavioral Therapy, Occupational Therapy, Physical Therapy, and Transcutaneous Electrical Nerve Stimulation (TENS). The Pharmacological Treatments is further studied across Anticonvulsants, Antidepressants, Nutritional Supplements, Opioid Analgesics, and Topical Agents.
  • Based on Stages Of Treatment, market is studied across Advanced Stage, Initial Stage, and Mid Stage.
  • Based on Patient Demographics, market is studied across Age Group, Gender, and Patient History. The Age Group is further studied across Adult, Geriatric, and Pediatric. The Gender is further studied across Female and Male. The Patient History is further studied across Genetic Factors, Pre-existing Conditions, and Previous Chemotherapy Treatments.
  • Based on Treatment Settings, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Duration Of Treatment, market is studied across Long Term and Short Term.
  • Based on Drug Mechanism Of Action, market is studied across Calcium Channel Modulators, Gamma-Aminobutyric Acid (GABA) Analogues, Opioids, and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs).
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of healthcare infrastructure and access in developing regions
      • 5.1.1.2. Collaborations between pharmaceutical companies and research institutions for novel therapies
      • 5.1.1.3. Government initiatives and funding to support cancer treatment and neuropathy management
      • 5.1.1.4. Integration of telemedicine and digital health solutions in neuropathy treatment protocols
    • 5.1.2. Restraints
      • 5.1.2.1. Challenges in clinical trial design for chemotherapy induced peripheral neuropathy treatments
      • 5.1.2.2. Regulatory hurdles in gaining approval for new chemotherapy induced peripheral neuropathy therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborating with pharmaceutical companies for breakthrough drug formulations targeting chemotherapy induced peripheral neuropathy
      • 5.1.3.2. Utilizing artificial intelligence and machine learning for personalized treatment plans in chemotherapy induced peripheral neuropathy
      • 5.1.3.3. Exploring dietary and lifestyle interventions to complement traditional chemotherapy induced peripheral neuropathy treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating the complexities of combination treatments for chemotherapy-induced peripheral neuropathy
      • 5.1.4.2. Challenges in clinical trial design and patient recruitment in neuropathy treatment market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Types

  • 6.1. Introduction
  • 6.2. Non-Pharmacological Treatments
    • 6.2.1. Acupuncture
    • 6.2.2. Cognitive Behavioral Therapy
    • 6.2.3. Occupational Therapy
    • 6.2.4. Physical Therapy
    • 6.2.5. Transcutaneous Electrical Nerve Stimulation (TENS)
  • 6.3. Pharmacological Treatments
    • 6.3.1. Anticonvulsants
    • 6.3.2. Antidepressants
    • 6.3.3. Nutritional Supplements
    • 6.3.4. Opioid Analgesics
    • 6.3.5. Topical Agents

7. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Stages Of Treatment

  • 7.1. Introduction
  • 7.2. Advanced Stage
  • 7.3. Initial Stage
  • 7.4. Mid Stage

8. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Patient Demographics

  • 8.1. Introduction
  • 8.2. Age Group
    • 8.2.1. Adult
    • 8.2.2. Geriatric
    • 8.2.3. Pediatric
  • 8.3. Gender
    • 8.3.1. Female
    • 8.3.2. Male
  • 8.4. Patient History
    • 8.4.1. Genetic Factors
    • 8.4.2. Pre-existing Conditions
    • 8.4.3. Previous Chemotherapy Treatments

9. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Settings

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Duration Of Treatment

  • 10.1. Introduction
  • 10.2. Long Term
  • 10.3. Short Term

11. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Drug Mechanism Of Action

  • 11.1. Introduction
  • 11.2. Calcium Channel Modulators
  • 11.3. Gamma-Aminobutyric Acid (GABA) Analogues
  • 11.4. Opioids
  • 11.5. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

12. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Asahi Kasei Corporation
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Biogen Inc.
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. Glenmark Pharmaceuticals Ltd.
  • 9. Ipsen Pharma
  • 10. Johnson & Johnson
  • 11. Kyowa Kirin Co., Ltd.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Purdue Pharma L.P.
  • 16. Regenacy Pharmaceuticals LLC
  • 17. Sanofi S.A.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INITIAL STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY MID STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENETIC FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PRE-EXISTING CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PREVIOUS CHEMOTHERAPY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG TERM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT TERM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY CALCIUM CHANNEL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GAMMA-AMINOBUTYRIC ACID (GABA) ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 218. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 219. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 230. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 240. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 241. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 242. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILL